Eugia Pharma Receives USFDA Approval for Fosaprepitant for Injection, 150 mg Single-Dose Vials
Published: January 12, 2021
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fosaprepitant for Injection, 150 mg Single-Dose Vials.
Indications for this product include:
- Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin;
- Prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Refer to package insert for full prescribing information.